Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide proof-of-concept study in pheochromocytoma
2006-006824-20Phase 2Terminated
- Sponsor
- Universitätsmedizin Essen
- Start
- Jul 2007
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pasireotide LAR in pheochromocytoma, sponsored by Universitätsmedizin Essen. Primary endpoint: Biochemical response rate after pasireotide. Started Jul 2007; status: terminated.
02
Drugs
pasireotide LAR
03
Conditions
pheochromocytoma
Beyond the preview
Go deeper on 2006-006824-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006824-20.